Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

ARS Pharmaceuticals (SPRY) Gains from Investment Securities (2021 - 2025)

Historic Gains from Investment Securities for ARS Pharmaceuticals (SPRY) over the last 5 years, with Q3 2025 value amounting to $300000.0.

  • ARS Pharmaceuticals' Gains from Investment Securities fell 9802.35% to $300000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $10.1 million, marking a year-over-year decrease of 3345.81%. This contributed to the annual value of $15.2 million for FY2024, which is 3191.11% up from last year.
  • According to the latest figures from Q3 2025, ARS Pharmaceuticals' Gains from Investment Securities is $300000.0, which was down 9802.35% from $17.3 million recorded in Q2 2025.
  • In the past 5 years, ARS Pharmaceuticals' Gains from Investment Securities ranged from a high of $17.3 million in Q1 2025 and a low of $100000.0 during Q4 2021
  • In the last 5 years, ARS Pharmaceuticals' Gains from Investment Securities had a median value of $9.2 million in 2024 and averaged $10.1 million.
  • Its Gains from Investment Securities has fluctuated over the past 5 years, first surged by 143333.33% in 2024, then plummeted by 9802.35% in 2025.
  • ARS Pharmaceuticals' Gains from Investment Securities (Quarter) stood at $100000.0 in 2021, then surged by 6925.51% to $7.0 million in 2022, then crashed by 91.46% to $600000.0 in 2023, then surged by 1433.33% to $9.2 million in 2024, then plummeted by 96.74% to $300000.0 in 2025.
  • Its Gains from Investment Securities stands at $300000.0 for Q3 2025, versus $17.3 million for Q2 2025 and $17.3 million for Q1 2025.